In This Article:
We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Elicio Therapeutics Inc (NASDAQ:ELTX) stands against the other healthcare stocks.
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI. The healthcare sector was a hot topic during the Stargate project announcement, so it is likely that there are going to be even more breakthroughs here as technology advances.
The S&P 500 Healthcare Index trailed the broader market considerably in the past few years. However, it has risen 7% year-to-date so far. There are many promising drugs awaiting approvals and trials right now. As such, healthcare EBITDA is projected to grow at a 7% CAGR, reaching $987 billion by 2028.
The sector is bouncing back from post-pandemic challenges. Nearly 60% of industry leaders expressed a favorable outlook for 2025. Thus, it is worth looking at the healthcare stocks spearheading the gains.
Methodology
For this article, I screened the top-performing healthcare stocks year-to-date. Stocks that I have covered recently will be excluded from this list.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A scientist in a white lab coat measuring liquid in a beaker in the biotechnology lab.
Elicio Therapeutics Inc (NASDAQ:ELTX)
Number of Hedge Fund Holders In Q3 2024: 1
Elicio Therapeutics Inc (NASDAQ:ELTX) is a biotech company that makes lymph node-targeted immunotherapies.
The stock has risen sharply so far in 2025 as it secured FDA agreement on some elements of its registrational Phase 3 trial design for ELI-002.
The company achieved full enrollment in its Phase 2 AMPLIFY-7P trial in Q1 2024. Interim DFS analysis is expected in the first half of this year.
Early data has shown a 28.9-month median DFS in Phase 1 patients receiving the 4.9mg dose, with T-cell responses correlating to reduced recurrence risk.
Plus, it raised $10 million via a registered direct offering priced at $7.925 per share.
The consensus price target of $10 implies 7.41% upside.